TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04144634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching exercises
Description: The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
Study: NCT01394653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral, with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral, with water
Study: NCT03207555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420 mg by mouth once daily.
Study: NCT04888325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose
Description: Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Description: 10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
Study: NCT02457312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: letrozole 10 mg daily for 7 days before suction evacuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
Study: NCT01395316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
Study: NCT01461239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiber post and resin core - self-adhesive cement
Description: pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cast post and core
Description: Ni-Cr alloy cast post and core luted with self-adhesive resin cement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiber post luted with conventional resin cement
Description: fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
Study: NCT02762812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-055

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade®
Study: NCT01004380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab, Carboplatin, and PLD
Description: All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
Study: NCT01885325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Preschool Intervention
Description: Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
Study: NCT01391585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message prompts
Description: In this single armed intervention, patients will receive text message prompts
Study: NCT04225221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
Study: NCT01988623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Study: NCT01395979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for Sexual Risk
Description: Eight weekly sessions, 4 modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Eight weekly sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Risk Reduction Intervention
Description: Two weekly sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Risk Reduction Intervention
Description: Two weekly sessions.
Study: NCT02710903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-induced biofilm overgrowth
Description: Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-induced biofilm overgrowth
Description: Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-induced biofilm overgrowth
Description: Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-induced biofilm overgrowth
Description: Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
Study: NCT02694939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAND (Behavior Therapy + Motivational Interviewing)
Description: Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Community Therapists free to deliver any therapy they feel is indicated.
Study: NCT03774966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block + Catheter & IPACK block
Description: Adductor Canal Block + Catheter \& IPACK block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block + catheter
Description: Adductor canal block + catheter
Study: NCT01096134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine (Gardasil)
Description: HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection
Study: NCT01406340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg GSK1278863
Description: 5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg GSK1278863
Description: 5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
Study: NCT01216384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive according to the dose group matching number of placebo tablets
Study: NCT02564926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
Study: NCT00232141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04637477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual ELM
Description: Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
Study: NCT00516243

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study: NCT02881957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral syrup placebo
Study: NCT02858869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT01351753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills and capsules for metformin, orlistat and topiramate
Study: NCT02916680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic islet transplantation in the anterior chamber
Description: Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
Study: NCT03330353

Intervention type: DIAGNOSTIC_TEST
Intervention: Pupillometry
Description: Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
Study: NCT00012298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oprelvekin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study: NCT01946841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RealDiet®Renal
Study: NCT03341351

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructional video
Description: Instructional video using the modified beef tongue model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructional workshop
Description: Instructional workshop using the modified beef tongue model.
Study: NCT01703663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPAP
Study: NCT00639210

Intervention type: OTHER
Group type: OTHER
Intervention: supervised training
Description: Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
Study: NCT00846547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
Study: NCT03591302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation
Description: Transplantation of hematopoietic stem cells from living donor.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid irradiation
Description: Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
Study: NCT00409773

Intervention type: DRUG
Group type: OTHER
Intervention: ezetimibe (+) simvastatin
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: ezetimibe (+) simvastatin
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: ezetimibe (+) simvastatin
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: ezetimibe (+) simvastatin
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: ezetimibe (+) simvastatin
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: atorvastatin calcium
Description: Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Study: NCT04396756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809
Study: NCT05269810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Low dose
Description: 3 tablets b.i.d for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Mid dose
Description: 3 tablets b.i.d for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 High dose
Description: 3 tablets b.i.d for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets b.i.d for 8 weeks
Study: NCT02164383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 4-week starter kit of nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 4-week starter kit of nicotine patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: 5 brief counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: 5 brief counseling sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Games
Study: NCT02390830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls Prevention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of limitations at body function and activity levels
Study: NCT01485354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring training
Description: Upper-limb training using the Armeo system for a period of 6 weeks
Study: NCT00575029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: 600 mg by mouth daily
Study: NCT04396756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00091949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: a thiazolidinedione drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance